REDMOND, Wash., Nov. 5, 2010 /PRNewswire/ -- Onconome, Inc. announced today that it was awarded a cash grant totaling approximately $231,000 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP was enacted as part of the Patient Protection and Affordable Care Act of 2010.
Onconome submitted a single grant application for its serum based Colon Cancer Rule Out Test currently in development. "We are very pleased to be among the companies chosen to receive a grant under this program," said Randy Brock, Onconome's President. "We believe our non-invasive Colon Cancer Rule Out Test now in development will give healthcare providers a valuable new tool to use in their overall approach to diagnosing this disease. Proceeds from the grant will be used to support ongoing development of this test."
About Onconome
Onconome, Inc. is a privately funded medical diagnostics company engaged in the use of mass spectrometry to identify protein patterns in serum that can indicate the absence of disease. Onconome has applied its non-invasive proteomics approach to both colon cancer and prostate cancer.
Contacts |
|
Onconome, Inc. |
|
Randy Brock, 425-284-4390, ext. 314 |
|
SOURCE Onconome, Inc.
Share this article